Endo, Mylan neurology news
Endo filed suit in the U.S. District Court for the District of Delaware against Mylan and its Mylan Pharmaceuticals Inc. subsidiary alleging that an ANDA for a generic version of migraine drug Frova frovatriptan infringes U.S. Patent Nos. 5,464,864, 5,637,611 and 5,827,871 covering the use of tetrahydrocarbazole derivatives as 5HT1 receptor agonists. The ANDA filing contained a Paragraph IV certification claiming that the patents are invalid and/or unenforceable, and that the claims in the patents would not be infringed by the ANDA. The patents expire in 2015, 2014 and 2015, respectively. Endo is seeking relief, that no ANDA be approved prior to the patent expirations and an enjoinder prohibiting the manufacturing or import of any generic version of Frova. ...